Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    20124187 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Condition: Metastatic Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Trastuzumab
2 Recruiting Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer
Conditions: Breast Neoplasms;   HER2 Protein, Human;   Geriatric Health Services
Interventions: Drug: Lapatinib;   Drug: Trastuzumab;   Other: laboratory biomarker analysis;   Other: pharmacological study

Indicates status has not been verified in more than two years